Replies to post #308925 on Avid Bioservices Inc (CDMO)

[shipbuilder]

biopharm, pphm and bms don't operate in a vacuum. If there is value in the Peregrine IP then it can go to the highest bidder. If it's so great it's not just going to be Bristol-Myers Squibb that's interested in it. All these machinations by one large pharmaceutical company can be hacked to pieces in an instant by anyone of another dozen pharmaceutical companies. Even if there is some unholy Eyes Wide Shut alliance between three of them, to sit on little PPHM, there are still 9 other monsters walking the Earth that could drop several billion dollars without flinching. So, whatever the evil of BMS/Ronin/Dr.No is, it's moot. All that matters is the validity of the IP. Am I wrong?

Also, $45 a share would be a market cap of $2.025B, not $1B

[north40000]

BMY seems to have suffered a bit from

[biopharm]

Novel technologies and emerging biomarkers for personalized cancer immunotherapy

Jianda Yuan1Email author,
Priti S. Hegde2,
Raphael Clynes3,
Periklis G. Foukas4, 5,
Alexandre Harari4,
Thomas O. Kleen6,
Pia Kvistborg7,
Cristina Maccalli8,
Holden T. Maecker9,
David B. Page10,
Harlan Robins11,
Wenru Song12,
Edward C. Stack13,
Ena Wang14,
Theresa L. Whiteside15,
Yingdong Zhao16,
Heinz Zwierzina17,
Lisa H. Butterfield18 and
Bernard A. Fox10

It looks like John Stafford left Xencor JUST IN TIME as he just missed the arrival of Raphael Clynes (ex BMS)


https://investorshub.advfn.com/boards/read_msg.aspx?message_id=131555041


-----

Portland-Based Immuno-oncologist Dr. Bernard A. Fox To Present at Siena, Italy Conference
...
...

“Now is the time to have this meeting, “ Fox said. “I applaud NIBIT for gathering academic investigators, important foundations and companies that are developing anti-OX40 and other T cell agonists to discuss conceptsaround dose, schedule, biomarkers, microbiome and the metabolome.”

Chief Medical Officer, The Cancer Research Institute, Aiman Shalabi, will address the opening session detailing current and prospectivecollaborations at NIBIT.

Other topics at the meeting include: How to further the development of immunotherapy; Biomarkers in peripheral blood; and Furthering the progress of new ideas in the field from young scientists.

“I am pleased to be able to attend this meeting and share UbiVac’s recent developments in this important area of research for a cancer cure,” Dr. Fox commented. “This is an international issue and an international quest. Clearly, global collaboration is proving necessary to reach our shared goal of conquering cancer with fewer side effects and less recurrence of the disease.”
..
https://www.oregonbio.org/2017/10/13/portland-based-immuno-oncologist-dr-bernard-a-fox-to-present-at-siena-italy-conference/